Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Dual/triple agonist

LY3305677 Lilly's Oxyntomodulin? New Ph1 Trial Observed

Here is a brief preview of this blast: A new Ph1 study of an early Lilly compound has been observed on CT.gov. LY3305677 is believed to be Lilly’s Ph1 injectable oxyntomodulin analog. Recall, in 2016, Lilly opted out of developing the Transition Therapeutics oxyntomodulin analog (TT401; now being developed by OPKO as OPK88003). Below, FENIX provides the rationale for why LY3305677 is likely Lilly’s oxyntomodulin and thoughts on its development in light of tirzepatide (GLP/GIP dual agonist) already moving to Ph3 in both T2DM and obesity.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.